FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2177276858> ?p ?o ?g. }

• W2177276858 endingPage "34" @default.
• W2177276858 startingPage "1424" @default.
• W2177276858 abstract "Atherosclerotic cardiovascular disease (ASCVD) has become the leading cause of death and disability in Thailand. Low-density lipoprotein cholesterol is the major risk factor of this condition that can be intervened by means of lifestyle modification and pharmacologic treatment. Adequacy of hypercholesterolemia treatment with lipid lowering drugs in Thailand needed to be more clarified. The present study was conducted to determine low-density cholesterol goal attainment in Thai population at risk for developing ASCVD.Twenty-seven physicians with their 909 hypercholesterolemic patients whose age of > or = 18 years, actively under pharmacologic treatment for at least three months with no dose adjustment for a minimum of six weeks from seven centers across Thailand were enrolled. Plasma glucose, total cholesterol, LDL cholesterol, HDL-cholesterol, and triglyceride levels were measured after overnight fast. Demographic and other relevant data including information on lipid lowering drug used were retrieved. Patients' awareness, knowledge on their management, compliance, and satisfaction were evaluated by questionnaire survey as well as physicians' use of guidelines, choice of management and goal setting, and their attitudes towards lipid management. Cardiovascular risk level and LDL goal were assessed by the updated 2004 NCEP-ATP III guidelines.All patients had LDL goal of < 130 mg/dl with 86.1% needed LDL goal of < 100 mg/dL. Overall, 52.7% of the patients reached their LDL goal. The most prescribed treatment was statin monotherapy (82.7%). LDL goal attainment was inversely associated with LDL goal set by NCEP-ATP III according to the patients' risk profile, with only 16.7% of those who were in the very high risk group with LDL goal of < 70 mg/dL achieved their goal whereas 60.6% and 84.7% of those with high (LDL goal < 100 mg/dl) and moderately high-risk (LDL goal < 130 mg/dl) achieved their goal, respectively (p < 0.001). Other factors associated with less favorable LDL goal attainment were coronary heart disease, carotid artery disease, diabetes, 10-year risk of > 20%, and metabolic syndrome (p < 0.05 for all). Type of lipid lowering drug was not significantly associated with LDL goal attainment.LDL goal attainment was not achieved in a high proportion of Thai patients especially in those who had high to very high risk for developing cardiovascular disease. Despite availability of well-established treatment guideline and efficacious lipid lowering drugs, many patients still miss the opportunity to effectively control their lipid profile." @default.
• W2177276858 created "2016-06-24" @default.
• W2177276858 creator A5014878489 @default.
• W2177276858 creator A5026850788 @default.
• W2177276858 creator A5064605967 @default.
• W2177276858 creator A5080693703 @default.
• W2177276858 creator A5082959013 @default.
• W2177276858 creator A5090957055 @default.
• W2177276858 date "2011-12-01" @default.
• W2177276858 modified "2023-09-23" @default.
• W2177276858 title "Lipid-lowering treatment in hypercholesterolemic patients: the CEPHEUS Thailand survey." @default.
• W2177276858 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22295727" @default.
• W2177276858 hasPublicationYear "2011" @default.
• W2177276858 type Work @default.
• W2177276858 sameAs 2177276858 @default.
• W2177276858 citedByCount "5" @default.
• W2177276858 countsByYear W21772768582015 @default.
• W2177276858 countsByYear W21772768582017 @default.
• W2177276858 countsByYear W21772768582019 @default.
• W2177276858 crossrefType "journal-article" @default.
• W2177276858 hasAuthorship W2177276858A5014878489 @default.
• W2177276858 hasAuthorship W2177276858A5026850788 @default.
• W2177276858 hasAuthorship W2177276858A5064605967 @default.
• W2177276858 hasAuthorship W2177276858A5080693703 @default.
• W2177276858 hasAuthorship W2177276858A5082959013 @default.
• W2177276858 hasAuthorship W2177276858A5090957055 @default.
• W2177276858 hasConcept C126322002 @default.
• W2177276858 hasConcept C134018914 @default.
• W2177276858 hasConcept C1862650 @default.
• W2177276858 hasConcept C2776839432 @default.
• W2177276858 hasConcept C2778163477 @default.
• W2177276858 hasConcept C2778913445 @default.
• W2177276858 hasConcept C2908647359 @default.
• W2177276858 hasConcept C71924100 @default.
• W2177276858 hasConcept C99454951 @default.
• W2177276858 hasConceptScore W2177276858C126322002 @default.
• W2177276858 hasConceptScore W2177276858C134018914 @default.
• W2177276858 hasConceptScore W2177276858C1862650 @default.
• W2177276858 hasConceptScore W2177276858C2776839432 @default.
• W2177276858 hasConceptScore W2177276858C2778163477 @default.
• W2177276858 hasConceptScore W2177276858C2778913445 @default.
• W2177276858 hasConceptScore W2177276858C2908647359 @default.
• W2177276858 hasConceptScore W2177276858C71924100 @default.
• W2177276858 hasConceptScore W2177276858C99454951 @default.
• W2177276858 hasIssue "12" @default.
• W2177276858 hasLocation W21772768581 @default.
• W2177276858 hasOpenAccess W2177276858 @default.
• W2177276858 hasPrimaryLocation W21772768581 @default.
• W2177276858 hasRelatedWork W2023333646 @default.
• W2177276858 hasRelatedWork W2029959808 @default.
• W2177276858 hasRelatedWork W2035484352 @default.
• W2177276858 hasRelatedWork W2041561513 @default.
• W2177276858 hasRelatedWork W2068269311 @default.
• W2177276858 hasRelatedWork W2110966479 @default.
• W2177276858 hasRelatedWork W2470736497 @default.
• W2177276858 hasRelatedWork W33581786 @default.
• W2177276858 hasRelatedWork W4235472535 @default.
• W2177276858 hasRelatedWork W2156030369 @default.
• W2177276858 hasVolume "94" @default.
• W2177276858 isParatext "false" @default.
• W2177276858 isRetracted "false" @default.
• W2177276858 magId "2177276858" @default.
• W2177276858 workType "article" @default.